Successful remission induction in refractory familial hemophagocytic lymphohistiocytosis with ruxolitinib as a bridge to hematopoietic stem cell transplantation

Pediatr Blood Cancer. 2020 Mar;67(3):e28071. doi: 10.1002/pbc.28071. Epub 2019 Nov 25.

Authors

Kesavan Melarcode Ramanan¹, Ramya Uppuluri¹, Nikila Ravichandran¹, Shivani Patel¹, Venkateswaran Vellaichamy Swaminathan¹, Indira Jayakumar², Revathi Raj¹

Affiliations

¹ Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Apollo Cancer Institutes, Teynampet, 600035, Chennai, India.
² Department of Pediatric Critical Care, Apollo Cancer Institutes, Teynampet, 600035, Chennai, India.

PMID: 31762142
DOI: 10.1002/pbc.28071

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Child, Preschool
Combined Modality Therapy
Drug Resistance
Female
Hematopoietic Stem Cell Transplantation / methods*
Humans
Lymphohistiocytosis, Hemophagocytic / pathology
Lymphohistiocytosis, Hemophagocytic / therapy*
Nitriles
Prognosis
Pyrazoles / therapeutic use*
Pyrimidines
Remission Induction
Transplantation Conditioning

Substances

Nitriles
Pyrazoles
Pyrimidines
ruxolitinib